What Half-Life Actually Means (And What It Does Not)
It appears on nearly every compound page in this library, and it is the number people most often misread. Half-life tells you how long something lingers — not how strongly it acts, and not what kind of compound it is.
What It Actually Measures
Half-life is the time it takes for half of a substance to be cleared from the body. If a compound has a half-life of one hour, then an hour after it enters the bloodstream roughly half remains. An hour later, half of that — a quarter. An hour after that, an eighth.
It is a measure of persistence, and nothing else. It says nothing about how powerfully a compound acts, what it does, or which family it belongs to. That single confusion is behind most of the mistakes people make reading this field.
Half-life, in plain language: imagine a room with a hundred people in it, and every hour half of whoever remains leaves. After one hour, fifty. After two, twenty-five. After three, twelve or thirteen. The room never empties completely on paper — but after four or five rounds there is effectively nobody left, and this is why the working rule is that a compound is largely gone after four to five half-lives. Notice too that the number describes how quickly people leave, not how loud they were while they were there. Persistence and effect are separate questions.
Why Some Compounds Last Minutes and Others a Week
The spread in this field is enormous. Natural GLP-1 survives about two minutes. Semaglutide, which is the same signal chemically modified, lasts about a week. Sermorelin is measured in minutes; Tesamorelin considerably longer. These are not differences in strength — they are differences in how quickly the body takes the molecule apart.
Peptides are cleared mainly by enzymes that cut them at particular points, and by the kidneys filtering small molecules out of the blood. Both processes are fast, which is why unmodified peptides tend to be short-lived. Extending a half-life means interfering with one or both.
The common strategies are worth recognising, because you will see them named on compound pages. Albumin binding attaches the peptide to a large blood protein so it is too big to be filtered out quickly — this is what semaglutide does. Structural modification changes the molecule at the exact points enzymes would cut, as with the modified GHRH fragments. Retro-inverso design, used in FOXO4-DRI, reverses the sequence and uses mirror-image amino acids so the enzymes no longer recognise it at all.
Why enzymes miss mirror-image molecules, in plain language: enzymes work by shape, like a hand fitting a glove. A left hand does not fit a right-handed glove no matter how hard you push. Building a peptide from mirror-image amino acids produces a molecule the enzyme simply cannot grip — the same shape in principle, but the wrong handedness in practice.
The Mistake People Make
The commonest error is treating a long half-life as evidence of a strong or advanced compound, and a short one as evidence of a weak or crude one. Neither follows.
Retatrutide and Tirzepatide are dosed weekly. That is a formulation property, achieved through chemistry. It tells you nothing about their mechanism — both are surface-signalling peptides, and so is semaglutide with the same weekly dosing. Meanwhile a bioregulator with a very short half-life is proposed to act at an entirely different level, on gene expression rather than at the cell surface. Duration and mechanism are separate axes, and a compound can sit anywhere on both.
The related error is assuming that when a compound clears, its effect ends. Sometimes that is true — a signalling peptide generally acts while the signal is present. But an effect can outlast the molecule that triggered it. That is precisely the claim made for bioregulators: that the change persists after the compound has gone. Whether that claim holds is an open question, but the logic is sound. A message and its consequences are not the same thing.
How to Read It on a Compound Page
When you see a half-life quoted, three questions make it useful rather than decorative.
Is it a measured value or an estimate? Well-studied pharmaceuticals have half-lives established in human trials. For many research compounds the figure is extrapolated from animal work, or from a structurally similar molecule, and should be read as approximate.
In what species? Clearance rates differ substantially between rodents and humans. A half-life measured in mice is not a human half-life, and the difference is frequently large.
Does it match the published dosing pattern? If a compound is described in trials as once-weekly, its half-life should be long enough to make that coherent. When the two do not line up, one of the numbers is wrong or is being quoted out of context.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Frontiers in endocrinology, 2019. PubMed
- Lau JL, Dunn MK. “Therapeutic peptides: Historical perspectives, current development trends, and future directions.” Bioorganic & medicinal chemistry, 2018. PubMed
- Werle M, Bernkop-Schnürch A. “Strategies to improve plasma half life time of peptide and protein drugs.” Amino acids, 2006. PubMed
- Baar MP, Brandt RMC, Putavet DA, et al. “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.” Cell, 2017. PubMed
Related Research Guides
More in Foundations
The four questions that separate a real finding from a headline.
Read guide →GLP-1 Receptor AgonistA worked example — how a two-minute signal was engineered into a week-long one.
Read guide →Essential ReadingThe foundational guide, including why duration and mechanism are separate questions.
Read guide →